Bivalirudin
Also known as: Angiomax, Angiox, BG-8967, Bivalirudin, Hirulog, PPACK analogue
Source Bivalirudin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Bivalirudin is a synthetic 20‑amino‑acid peptide that directly inhibits thrombin. It is approved for use as an anticoagulant during percutaneous coronary interventions and is employed off‑label in settings such as extracorporeal membrane oxygenation (ECMO) and heparin‑induced thrombocytopenia. By blocking both the active site and fibrin‑binding exosite of thrombin, it prevents clot formation while offering a predictable anticoagulant effect.
Mechanism of Action
Bivalirudin binds thrombin at two sites: the catalytic active site via its N‑terminal tetrapeptide and the fibrin(ogen)‑binding exosite I via its C‑terminal region, linked by a tetraglycine spacer. This bivalent interaction blocks both circulating and fibrin‑bound thrombin, halting conversion of fibrinogen to fibrin. The peptide is subsequently cleaved by proteases, which reversibly terminates inhibition. Clearance occurs through proteolytic degradation and renal filtration, giving it a mixed metabolic profile.
What the Research Shows
Reviews of ECMO anticoagulation highlight bivalirudin as a valuable alternative to unfractionated heparin, especially in patients with heparin‑induced thrombocytopenia, though cost and availability limit use. A 2005 pharmacology review reported that bivalirudin provides a predictable anticoagulant effect, prolongs standard clotting times, and shows comparable efficacy to heparin with less major bleeding in percutaneous coronary intervention (PCI). A prospective pediatric ECMO pilot trial (16 bivalirudin vs 14 heparin) found similar time at goal anticoagulation, comparable bleeding, but a higher rate of circuit thrombosis with bivalirudin and lower red‑cell transfusion. Factor V Leiden testing literature notes that direct thrombin inhibitors, including bivalirudin, can interfere with activated protein C resistance assays.
Reported Benefits
Clinical data in PCI indicate that bivalirudin reduces in‑hospital major bleeding compared with heparin, while maintaining similar efficacy for preventing ischemic events. It is safe in patients with heparin‑induced thrombocytopenia and offers a predictable anticoagulant profile that is less dependent on renal clearance than some alternatives. In pediatric ECMO, bivalirudin was associated with fewer packed red‑cell transfusions, suggesting reduced bleeding burden.
Limitations of the Evidence
Large, head‑to‑head randomized trials versus unfractionated heparin are lacking for many indications, including ECMO and cardiac surgery. The pediatric ECMO pilot reported a higher incidence of circuit thrombosis with bivalirudin, indicating potential safety concerns in that setting. Monitoring ACT does not correlate with clinical effect, complicating dose titration. Cost, limited availability, and the need for intravenous infusion also restrict broader adoption.
Safety Considerations
Bivalirudin is generally well tolerated with low immunogenicity, but bleeding remains a risk, similar to other anticoagulants. In ECMO studies, hemorrhagic complications were comparable to heparin, while circuit thrombosis was higher in the bivalirudin arm. Renal impairment can reduce clearance, necessitating dose adjustment. No specific antidote exists, and reversal relies on cessation of infusion and supportive measures.
How It Is Administered
Bivalirudin is administered exclusively by intravenous infusion, typically as a continuous infusion following an initial bolus. Formulations are supplied for parenteral use; no oral or subcutaneous preparations are available. Dosing regimens vary by indication and patient characteristics and are guided by institutional protocols and laboratory monitoring.
Routes of Administration
Goals & Uses
- Prevention of acute stent thrombosisTherapeuticHigh
- Management of heparin-induced thrombocytopenia (HIT)AnticoagulationHigh
- Anticoagulation during percutaneous coronary intervention (PCI)AnticoagulationHigh
- Anticoagulation during ECMOAnticoagulationLow
- Reduction of bleeding complications in ACSHemostasisHigh
- Anticoagulation during cardiac surgery (off-pump/CABG)AnticoagulationModerate
- Anticoagulation during PCIProceduralHigh
Contraindications
- Severe renal impairment (GFR <30 mL/min) without dose adjustmentRenalModerate
- Known hypersensitivity to bivalirudin or any excipientsAllergyHigh
- Active major bleedingHemorrhagic RiskHigh
- Severe hypersensitivity to bivalirudin or hirudin analogsAllergy/ImmunologyHigh
Adverse Effects
- Injection site reactionsLocalUncommon
- Hypersensitivity/anaphylaxisImmunologicalRare
- ThrombocytopeniaHematologicRareLow platelet count
- Acute stent thrombosisThromboticUncommon
- HypotensionCardiovascularUncommonLow blood pressure
- Nausea/vomitingGastrointestinalUncommon
- Allergic reactions (rash, urticaria)ImmuneRare
- BleedingHematologicCommonAbnormal bleeding or hemorrhage
- Bleeding (minor and major)HemorrhagicCommon
Drug Interactions
- Antiplatelet agents (e.g., clopidogrel, aspirin)Moderate
- WarfarinModerate
- Thrombolytics (e.g., alteplase, tenecteplase)High
- Glycoprotein IIb/IIIa inhibitors (e.g., abciximab, eptifibatide)Moderate
- Other anticoagulants (e.g., heparin, warfarin, DOACs)High
- Low molecular weight heparins (LMWHs)High
- Unfractionated HeparinHigh
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionApprovedApproved: Anticoagulation during PCI, Unstable anginaAuthorized under similar indications as US.
- United StatesApprovedApproved: Anticoagulation during percutaneous coronary interventionMarketed as Angiomax.
- United KingdomApprovedApproved: Anticoagulation in adults undergoing PCI, STEMI patients undergoing primary PCIRetained EU approval post-Brexit; marketed as Angiox in the UK.
FDA‑approved in 2000 (Angiomax) for use in percutaneous coronary intervention; also approved in the EU and Canada.
Evidence & Sources
- Journal ArticleModerateVajter J, Volod O2025-01-01T00:00:00.000000Z
- Journal ArticleModerateShammas NW2005-01-01T00:00:00.000000Z
- Journal ArticleModerateMcMichael A, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateVan Cott EM, Khor B, Zehnder JL2016-01-01T00:00:00.000000Z
- Journal ArticleModerateWarkentin TE, Koster A2005-01-01T00:00:00.000000Z
Frequently Asked Questions
What makes bivalirudin different from unfractionated heparin?
Bivalirudin directly binds and inhibits thrombin at two sites, does not require antithrombin, and its anticoagulant effect is more predictable. It also has a lower incidence of major bleeding in PCI and can be used in heparin‑induced thrombocytopenia.
Can bivalirudin be used for patients on ECMO?
Yes, it is used off‑label as an alternative anticoagulant during ECMO, especially when heparin is contraindicated. Small studies suggest similar anticoagulation control but have reported more circuit thrombosis, indicating that larger trials are needed.
How is bivalirudin cleared from the body?
The peptide is eliminated by proteolytic cleavage and renal filtration. Because part of its clearance is metabolic, dependence on kidney function is less than with some other anticoagulants, though renal impairment still requires dose consideration.
Is there an antidote for bivalirudin if bleeding occurs?
No specific reversal agent exists. Management relies on stopping the infusion and providing supportive care, such as transfusion of blood products, until the drug’s activity wanes.
Why might bivalirudin interfere with certain laboratory tests?
Direct thrombin inhibitors can affect activated protein C resistance assays and other clot‑based tests, leading to discrepant results when evaluating conditions like Factor V Leiden.
What is Bivalirudin?
Bivalirudin is a synthetic 20‑amino‑acid peptide that directly inhibits thrombin. It is approved for use as an anticoagulant during percutaneous coronary interventions and is employed off‑label in settings such as extracorporeal membrane oxygenation (ECMO) and heparin‑induced thrombocytopenia. By blocking both the active site and fibrin‑binding exosite of thrombin, it prevents clot formation while offering a predictable anticoagulant effect.
What is Bivalirudin used for?
Bivalirudin is educationally associated with: Prevention of acute stent thrombosis, Management of heparin-induced thrombocytopenia (HIT), Anticoagulation during percutaneous coronary intervention (PCI), Anticoagulation during ECMO, Reduction of bleeding complications in ACS, Anticoagulation during cardiac surgery (off-pump/CABG), Anticoagulation during PCI. Educational only — not medical advice.
How is Bivalirudin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Bivalirudin?
Reported adverse effects include: Injection site reactions, Hypersensitivity/anaphylaxis, Thrombocytopenia, Acute stent thrombosis, Hypotension, Nausea/vomiting, Allergic reactions (rash, urticaria), Bleeding, Bleeding (minor and major). This list is not exhaustive — consult a qualified clinician.
Who should avoid Bivalirudin?
Recorded contraindications: Severe renal impairment (GFR <30 mL/min) without dose adjustment, Known hypersensitivity to bivalirudin or any excipients, Active major bleeding, Severe hypersensitivity to bivalirudin or hirudin analogs. Consult a qualified clinician before use.